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Abstract
Age-associated atrophy of the thymus with coincident reduction in thymopoeisis, decline in thymic output, and
subsequent immune dysfunction has been reversed by the use of interleukin-7 (IL-7). In the earlier studies and in
clinical trials, delivery of IL-7 has been by multiple injections over several days to maintain effective activity
levels in the tissues. This is unlikely to meet with high compliance rates in future clinical use, and so we tested
alternate routes of delivery using a technique involving tagging IL-7 with fluorescent dye that emits in the near-
infrared region and whose fluorescence can be visualized within the tissues of live animals. We have shown that
intratracheal instillation, enabling transfer through the lungs, provides an effective route for delivering IL-7 into
the bloodstream and from there into the tissues in older animals. Delivery is rapid and widespread tissue
distribution is seen. Comparison of administration either subcutaneously or by instillation reveals that IL-7
delivery by the pulmonary route provides significantly greater transmission to lymphoid tissues when com-
pared with injection. In functional assessment studies, pulmonary administration led to significantly improved
intrathymic T cell development in older animals when compared with IL-7 delivered by injection. Furthermore,
in these older animals, delivery of IL-7 by intratracheal instillation was not accompanied by any apparent
adverse events when compared with controls receiving saline vehicle by instillation or animals receiving IL-7 by
subcutaneous injection.
Introduction
Interleukin-7 (IL-7) is a type 1 short-chain cytokine of thehematopoietin family and plays a central role in the de-
velopment and maintenance of T cells. The human IL-7 gene
consists of 6 exons on chromosome 8q12–13 that together
code for a protein whose molecular weight is 25 kD after
glycosylation.1 The protein can be detected in many stromal
tissues, including epithelial cells in the thymus, bone marrow
and gut, keratinocytes, liver, dendritic cells,1 and also as-
trocytes.2 The action of IL-7 is mediated through the binding
of the protein to a cell-surface receptor composed of two
chains, a (CD127) and c (CD132). The first step in this process
is the interaction of IL-7 with the IL-7 receptor a (IL-7Ra)
chain, forming a stable 1:1 intermediate. This then interacts
with the c-chain, forming an active ternary complex, and the
amalgamation of these two chains by IL-7 orients their cy-
toplasmic domains so that their respective kinases can
phosphorylate sequence elements on the cytoplasmic do-
mains. Transcriptional activators bind to the phosphorylated
sequence elements of these chains and become phosphory-
lated, after which they dissociate from the chains, oligo-
merize, and move to the nucleus, where they initiate
transcriptional activity.3
Decline in thymic activity with advancing age in animal
models has been shown to be associated with a reduction in
the level of expression in the thymus of IL-7.4,5 Some studies
report that treatment of old animals with IL-7 reverses thy-
mic atrophy, increases thymopoeisis, and improves thymic
output, boosting immune function.6–9 However others report
that IL-7 introduced into the thymus was unable to impact
on thymic involution or increase T cell output, possibly be-
cause of reduced proliferation of the DN4 population of
cells.10 These studies followed earlier animal studies, which
provided promising results and suggested that IL- 7 could
have significant potential in the clinic for assisting in the
treatment of viral infections such as human immunodefi-
ciency virus (HIV) and boosting immune recovery after bone
marrow transplantation.
Clinical trials with IL-7 have been initiated and the treat-
ment regimen is normally subcutaneous injection of IL-7 in a
saline vehicle every 2 or 3 days over a 2- to 3-week period.11–17
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Although this route of administration is efficient and neces-
sary to achieve effective levels within the tissues, it has
limitations associated with maintenance, distribution, and
compliance.
If IL-7 is to be of therapeutic benefit to older individuals in
reversing age-associated immune decline, its take up as a
therapeutic agent will be hampered if it is to be injected
repeatedly. This may be an acceptable form of delivery
when patients are confined to hospital, but it would be un-
acceptable for any therapeutic agent designed for use in the
community. Improved compliance would require finding
alternatives to repeated parenteral delivery.
The aim of this study was to determine whether delivery
of IL-7 by the pulmonary route would provide efficient
systemic distribution as well as an effective means of targeting
IL-7 to the thymus. We followed the trajectory of IL-7 after
administration by conjugating IL-7 to a near-infrared dye that
could be detected in deeper tissue sites after fluorescent acti-
vation and enabled real-time visualization of its movement,
distribution, and kinetic turnover in vivo. Although the pul-
monary route is often used for the delivery of proteins and
peptides, there are safety concerns because of the possibility of
immune-mediated reactions.18 Therefore, this study also
aimed to note whether there were any adverse events asso-
ciated with intratracheal delivery in this instance.
Materials and Method
Mice
Inbred C57BL/6 female mice were obtained from Charles
Rivers and housed according to the local rules and regula-
tions.
Conjugation of IL-7 to IRDye 800CW
Recombinant murine (rm) IL-7 (R&D Systems, Abingdon,
UK) was conjugated to the infrared fluorescent dye IRDye
800CW (LI-COR Biosciences, Cambridge, UK) according to the
manufacturer’s instructions. Briefly, the lyophilized IL-7 was
reconstituted with filter-sterilized phosphate-buffered saline
(PBS) to a final concentration of 100lg/mL, and 1 mg of rmIL-7
was mixed with 15.5lL of IRDye 800CW and incubated in the
dark at room temperature for 2 hr. Afte conjugation, residual
unbound dye was removed using a Pierce ZebaTM Desalting
Spin Column (Thermo Fisher Scientific, Northumberland, UK).
Aliquots of the conjugated protein at concentration of 1lg/
25lL were stored at - 40C until required.
As a control, we used a nonreactive carboxylated form of
the IRDye 800CW (LI-COR Biosciences, Cambridge, UK),
prepared by reconstitution of the dye with filter-sterilized
PBS. The dye was subsequently stored at - 40C until re-
quired. The labeling ratio and the concentration of the con-
jugated protein (IL-7-800CW) were estimated by using the
extinction coefficients of IL-7 (e280nm = 8,970 M - 1cm - 1) and
CW800 (e777nm = 270,000 M - 1cm - 1) in PBS:methanol, with
correction for the 3.0% of measured absorbance at 280 nm
attributable to CW800: Labeling ratio = (Abs777nm/e777nm)/
[(Abs280nm - 0.03*Abs777nm)/e280nm].
Treatment regimens
The C57BL/6 female mice used in these experiments were
separated according to age. Young mice (9–12 weeks of age)
were used to compare delivery of IL-7 either by injection or
instillation. Injections were carried out subcutaneously. In-
stillation into the lungs was performed using a microsprayer
(Model FMJ-250, Penn-Century Inc., USA) inserted into the
oropharyngeal tube in mice anesthetized with ketamine and
xylazine where the trachea had been visualized with the
mouse in a prone position as previously described.19 Ani-
mals were instilled with either the carboxylate dye or 1 lg of
recombinant IL-7-800CW. All animals were visualized in real
time for 48 hr using the LI-COR Pearl imaging system be-
fore being culled and tissues collected for analysis.
Older animals (12 months of age) were used to compare
the efficacy of the delivery. Animals were given three doses
of either 1 lg of recombinant IL-7 or saline vehicle alone on
alternate days by instillation to the lungs as described above
or alternatively were given three doses of either 1 lg of re-
combinant IL-7 or saline vehicle alone by subcutaneous in-
jection after receiving anesthesia similar to that given to
animals receiving instillation. These groups of animals were
culled 15 days after the initiation of treatment.
Tissue analysis
Tail blood was collected from animals at 1, 24, and 48 hr as
described previously20 to determine the circulating concen-
tration of IL-7-800CW. A total of 20 lL of blood was collected
at each time point. The samples were frozen at - 20C until
analyzed, at which point the blood samples were diluted at a
ratio of 1:5 in PBS and 50 lL of the diluted samples were
transferred to microtiter plates (Corning, UK) and imaged
using the LI-COR Pearl imaging system to determine the
fluorescent intensity reading.
Tissue distribution
The mice were killed by CO2 asphyxiation followed by
cervical dislocation. To determine the tissue distribution of
the IL-7-800CW, different organs were collected, including
lungs, spleen, thymus, liver, kidney, and lymph nodes. The
organs were weighed and then either homogenized imme-
diately or for long-term storage placed in 2 mL of RNAlater
(Ambion) solutions at 4C prior to transfer to - 80 C ac-
cording to the manufacturer’s instructions.
The tissues were homogenized with the Precellys24 ho-
mogenizer (Bertin-Cepheid, Derbyshire), briefly. The organ
was placed into a 2-mL tube containing 1.5 mL of 10% Dul-
becco modified Eagle medium (DMEM) in PBS and small
ceramic beads (CK14) for the Precellys (Bertin-Cepheid,
Derbyshire). The thymus was homogenized at 5,100 rpm for
5 sec and the spleen and lung at 5,000 rpm for 8 sec. The
homogenized tissue was strained using a cell strainer to re-
move any cellular debris, and the concentration and cellular
viability of the cellular suspension was determined using a
Countess Automated Cell Counter (Invitrogen, UK). Ali-
quots of 1 · 107 cells were either viably stored in fetal calf
serum (FCS) and 10% dimethylsulfoxide (DMSO) or the cells
were stained with appropriate fluorescently labeled anti-
bodies as described previously.7 Briefly, approximately 106
cells were incubated in a volume of 100 lL of PBS supple-
mented with FCS along with 1 lg of fluorescently tagged
antibody or its appropriate isotype control for approximately
30 min at 4C. The cells were then washed by centrifugation
and resuspended in PBS and either analyzed immediately or
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fixed for analysis later. Analysis was carried out on an Accuri
C6 flow cytometer.
Statistical analysis
The results of the descriptive tissue analysis are presented
for numerical variables in the form of means – standard de-
viation, and percentage was calculated for categorical out-
comes. Statistical tests used for the comparative analysis
between treatment groups were chosen according to the type
of variable, the sample size under consideration, and the
number of groups compared. Thus, numerical outcomes were
tested using the Mann–Whitney test; the Fisher exact test was
chosen for categorical outcomes. Specifically, analysis of the
relative fluorescent signal detected from different animal or-
gans according to the delivery route (instilled vs. injected) and
the treatment administrated (IL-7 vs. carboxylate) were com-
puted with the procedure PROC MIXED for the generalized
linear model using repeated data. Indeed, to reduce the var-
iance of estimates of treatment effects, triplicate fluorescent
signal detections analyses were performed for each organ and
each subject irrespective of treatment or delivery route.
The level of significance was set at p = 0.05. All analyses
were performed using SAS software version 9.1 (SAS Sys-
tem, SAS Institute Inc., Cary, NC).
Results
Comparing delivery routes for IL-7
These experiments were carried out on young animals.
Preliminary experiments were carried out to determine the
distribution in the lungs of IL-7-800CW, 1 hr after instillation.
Our results (Fig. 1) revealed that intratracheal instillation
produces a clear and apparently even distribution of the la-
beled IL-7 throughout the lungs. Once there was evidence
that instillation in the lungs could provide an effective means
of delivery, comparative analysis of the routes of delivery
was carried out. Animals were treated with a single dose of
1 lg of labeled IL-7 delivered either by intratracheal instil-
lation or by subcutaneous injection. Comparisons of the
scanned images from both methods of delivery are shown in
Fig. 2. These suggest that IL-7 is disseminated to the tissues
when delivered through the lungs and that much of the IL-7
remains at the site of delivery when injected subcutaneously.
The administered IL-7 circulating in peripheral blood was
determined by measuring the fluorescent signal obtained at
1, 24, and 48 hr postadministration. The results of fluorescent
signal measurement in the blood (Fig. 3) show that at 1 hr
and 48 hr after delivery there was no significant difference in
the fluorescence in the blood between instillation versus in-
jection delivery methods ( p > 0.05 at 1 hr and at 48 hr, where
n = 4 for inhalation and n = 5 for injection at both time points).
This would indicate that there was no significant decline in
the amount of IL-7 in the blood over this time.
To eliminate the possibility that the detectable fluorescent
signal within the circulation was due to unbound free dye,
animals received a fluorescent nonreactive carboxylated free
dye as a control. A relatively high level of signal was de-
tected at 1 hr postadministration, and this diminished rap-
idly to only 15% of this value at 1 hr; by 48 hr it was just
under 6% of the 1-hr value and considerably less than the
labeled IL-7 value at 48 hr postadministration (Fig. 3).
To compare different delivery routes on the accumulated
tissue-specific concentrations of IL-7, organs, including thy-
mus, lungs, heart, spleen, kidney, and liver, were tested at
FIG. 1. Fluorescent imaging of distribution of labeled
interleukin-7 (IL-7) in a young animals within the lung ap-
proximately 60 min after intratracheal instillation of 500 ng of
labeled IL-7.
FIG. 2. Detection of fluorescence in single young animal at
timed intervals after the instillation or injection of labeled inter-
leukin-7 (IL-7). Each image is a ventral view and the approximate
time after administration is shown at the side of each image.
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48 hr after delivery. There was a significant difference in the
relative fluorescence signal from the labeled IL-7 in the lungs
( p = 0.0005) when comparing instillation versus injection
routes, as expected. However for other organs there was no
significant difference ( p > 0.05) between instillation and in-
jection in the nonlymphoid organs (heart, kidney, and liver),
but significantly more signal in the thymus ( p = 0.02) and the
spleen ( p = 0.007) following delivery by instillation when
compared with delivery by injection (Fig. 4).
The carboxylate-treated control animals had lower detectable
signals, indicating limited maintenance of the free dye and
suggesting that the increased fluorescent signal in the IL-7–
treated group was due to retention of IL-7. For example, the
signal thymic tissue was significantly higher when labeled IL-7
was delivered either by injection ( p = 0.004) or instillation
( p = 0.004) when compared to delivery of carboxylate dye.
Comparison of functional effect
of different delivery routes
Having established the feasibility of the instillation
method for delivery of IL-7 and compared it with other de-
livery routes, the next stage was to establish the functional
and physiological impact of the instilled intratracheal lung
route compared to the injected route of delivery. These ex-
periments were carried out on older animals.
We compared the effect of the different routes of treatment
on the thymus and the results (Table 1) revealed that there
was no significant difference between the total number of
thymocytes in animals receiving treatment by instillation,
nor between animals receiving treatment by injection, nor
between those receiving IL-7 by inhalation and injection
( p > 0.05 in all cases). Furthermore, there was no significant
FIG. 3. Relative fluorescent signal detected from peripheral
blood samples in young animals taken over a 48-hr time period
using different routes of administration of labeled interleukin-7
(IL-7) or the free carboxylate dye control. Figures are the average
values obtained from between two to five samples. Free car-
boxylate dye was instilled into the lungs (open triangles) or in-
jected subcutaneously (open circles) and compared with tagged
IL-7 instilled into the lungs (closed circles) or injected subcuta-
neously (closed triangles).
FIG. 4. Relative fluorescent signal per milligram of tissue detected from different organs of young animals receiving labeled
interleukin-7 (IL-7) (shaded columns) or carboxylate dye (open columns) by instillation or injection.
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difference between the number of double-positive cells
within each of these categories ( p > 0.05 in all cases). How-
ever, the animals receiving IL-7 by inhalation showed more
triple-negative cells than animals in the other groups. In view
of this, we analyzed the early stages of T cell development in
IL-7–instilled animals compared with PBS-instilled animals
(Table 2). Representative samples of fluorescent profiles from
each treatment (Fig. 5) suggest that instillation may provide
the best route of delivery. These early stages are components
of the triple-negative (CD3- CD4- CD8- ) subset of the thymus
whose numbers are increased in IL-7–instilled animals com-
pared with the PBS controls (Fig. 6), where it is apparent that
the contribution of the CD44 + CD25 + subset toward the
overall triple-negative population is increased after IL-7 in-
stillation from 3% to 21% ( p < 0.0001). Comparison of the in-
stilled versus injected route reveals significant improvements
in all of the early subsets of the T cell development pathway in
instilled animals compared with injected animals (Fig. 7).
Finally, concern was raised over whether instillation of
IL-7 in the lung would prove stressful for the animals and in
addition could lead to attraction of inflammatory mononu-
clear cells to the lung or proliferation of resident mononu-
clear cells. Using weight change as a surrogate marker for
stress, we saw no significant weight loss ( p > 0.05 at all time
points when compared to the starting weight) in the animals
throughout the treatment period (Fig. 8A). Analysis of the
total number of cells in the larger left lobe of treated animals
(Fig. 8B) revealed significantly fewer cells in the animals
instilled with IL-7 compared with those receiving IL-7 in-
jected subcutaneously ( p = 0.002).
Discussion
Provision of proteins for therapeutic use by routes other
than injection is limited to some extent by the efficiency with
which the protein can cross the epithelial barrier. Here we
Table 1. Total Cell Number and Average Number of Cells in Each Population – 1






CD4 + CD8 + cells
Number of
CD4 + CD8 - cells
Number of
CD4 - CD8 + cells
IL-7 instillation (n = 7) 2.76 – 1.82 · 108 3.31 + 2.42 – 107 1.56 – 1.01 · 108 7.63 – 5.16 · 107 1.68 + 1.21 · 107
PBS instillation (n = 8) 3.36 – 1.19 · 108 1.6 – 0.99 · 107 2.49 – 1.12 · 108 5.6 – 0.8 · 107 1.29 – 0.43 · 107
IL-7 injection (n = 9) 1.61 – 0.9 · 108 4.18 – 6.89 · 106 1.41 – 0.8 · 108 1.44 – 1.07 · 107 3.13 – 3.56 · 106
PBS injection(n = 9) 3.33 – 2.29 · 108 8.97 – 6.12 · 106 2.59 – 1.9 · 108 4.84 – 3 · 107 1.29 – 0.76 · 107
TN, triple negative; IL-7, Interleukin-7; PBS, phosphate-buffered saline.
Table 2. Average Number of Cells in Each Subpopulation of the TN Subset
after Treatment of Older Animals
Early stage T cell development subpopulations
Treatment CD44 + CD25 - CD44 + CD25 + CD44 - CD25 + CD44 - CD25 -
IL-7 instilled (n = 7) 1.14 · 107 7.01 · 106 4.5 · 106 1.02 · 107
PBS instilled (n = 8) 5.5 · 106 5.56 · 106 2.61 · 106 7.33 · 106
TN, triple negative; IL-7, interleukin-7; PBS, phosphate-buffered saline.
FIG. 5. Representative examples of the fluorescent profiles obtained for the subsets defined by expression of CD44 and
CD25 within the CD3 - CD4 - CD8 - population from older animals who received interleukin-7 (IL-7) (A) or phosphate-
buffered saline (PBS) (B) through the instillation route or IL-7 (C) or PBS (D) by injection.
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have shown that IL-7, which is normally delivered in the
clinic by repeated subcutaneous injection, can be effectively
delivered as a therapeutic agent through the lungs. In terms
of efficiency, our tagging experiments suggest that pulmo-
nary delivery is at least as efficient as subcutaneous injection,
whereas our functional experiments suggest that pulmonary
delivery may be more efficient at producing an effect when
compared with injection.
Previous studies to analyze the presence and distribution
of IL-7 in the tissues after injection have distinguished be-
tween introduced and endogenously produced IL-7 on the
basis of amount detected by enzyme-linked immunosorbent
assay (ELISA)21 or have discriminated between these differ-
ent sources of the IL-7 by radioactive labeling that which was
injected.22 Tagging with dyes that fluoresce in the near-
infrared region of the spectrum offers a safer alternative to
FIG. 6. Pie chart showing the distribution of the minor subsets within the CD3 - CD4 - CD8 - population, showing the
averages and the percentage contribution of n = 7 (interleukin-7 [IL-7] instilled shown in A) and n = 8 (phosphate-buffered
saline [PBS] instilled shown in B) older animals. Total numbers of the CD3 - CD4 - CD8 - population are shown below each pie
chart.
FIG. 7. Comparison between interleukin-7 (IL-7)–instilled and IL-7–injected older animals of the numbers of cells within
each minor subset of the CD3 - CD4 - CD8 - population.
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studies involving radioactive labels and furthermore allowed
us to follow the adsorption kinetics and distribution of the
drug in real time. This provides considerable animal sparing
when compared with other techniques.
A confounding factor in the delivery of IL-7 is its capacity
to bind to heparin and heparin sulfate. Because heparin
is produced by cells within connective tissue, it is found
intracellularly in most tissues and also in serum; heparin
sulfate is present in extracellular matrices, basement mem-
branes, and cell surfaces.23 In addition, the amount of hep-
arin varies with age,24 and the ability to bind IL-7 could alter
the distribution profile of any IL-7 introduced into the body
and its availability at the target organ. We noted prolonged
maintenance of IL-7 at the site of subcutaneous injection, but
such prolongation within the lungs was not as apparent.
We were aware that some of the IL-7 could be maintained
on the air side of the epithelium either through binding to
intracellular components in the epithelium or by virtue of its
molecular size, which may inhibit its rapid transepithelial
transit.25 Prolonged maintenance within the lung could lead
to enzymic degradation of the tagged IL-7 through the action
of proteases or peptidases.25 However, the observation that
48 hr after instillation the amounts of fluorescence in the
bloodstream were similar to that seen via the injection route,
which was considerably more than that seen with the free
dye, and the reports showing that more than 95% of proteins
such as albumin instilled into the airways may reach the
circulation (reviewed in ref. 25) would suggest that the IL-7
from pulmonary delivery found in the bloodstream was as
intact as that delivered by injection.
Whether IL-7 delivered through the lungs was functional
was tested in older animals. Previous work has shown that
IL-7 production in the epithelial component of the thymus
declines with age4 and that introduction of IL-7 can lead to a
reversal of thymic atrophy with increases in the minor and
major subsets of the thymus.6,7,26 IL-7 when instilled into the
lungs appeared to be able to rapidly transit into the blood-
stream and remain at levels commensurate with subcutane-
ous injection. Organ distribution measured by fluorescent
signal appeared to significantly favor instillation over injec-
tion when these two routes were compared. However, use of
fluorescence alone may hide the possibility of degeneration
of the attached IL-7 to a nonfunctional state. Experiments in
older animals to assess functional capability again revealed
that instillation proved to be significantly better than injec-
tion. This was shown by the effect on the early stages of T cell
development within the CD3 - CD4 - CD8 - population.
These populations, defined by their expression of CD44 and
CD25, express the IL-7 receptor, and this would account for
the increase in the animals instilled with IL-7 compared with
the PBS controls. The differences between the values ob-
tained from the instilled versus injected IL-7 would suggest
that instillation is more effective than injection at delivering
functional amounts of IL-7 to the thymus.
Because IL-7 is a growth and survival factor for lympho-
cytes, which in their turn may produce factors engendering
inflammation, it was possible that instillation could induce
expansion or recruitment of mononuclear cells associated
with inflammation in the lung. However, our analysis re-
vealed that following a single instillation there was no major
differences between mice receiving the IL-7 by instillation
and the control groups, suggesting that rapid transit of IL-7
through the epithelium may have prevented any build-up
within the lungs.
Use of the pulmonary system as a delivery route for
mammalian proteins provides opportunities for rapid dis-
semination into the bloodstream, provided the molecule can
cross the epithelial barriers into the lungs and then enter the
organs and tissues from the bloodstream. Although in gen-
eral molecules above 6 kD should be able to transit the lung
epithelium,27 there is some variability based on susceptibility
to peptidase and molecular size. We have shown here that
FIG. 8. Relative weight change in older animals receiving
interleukin-7 (IL-7) by instillation (n = 7) at times during the
procedure (A) and comparison of the total number of
mononuclear cells within the large left lung lobe of mice (B)
treated by instillation or injection. PBS, Phosphate-buffered
saline.
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IL-7 can transit the lungs, enter the bloodstream, and have
effector function in the relevant organs. This has implications
on the future therapeutic uses of IL-7 because inhalation may
provide a means of extending the place of drug delivery
from the clinic to the community. IL-7 has been shown to
broaden responses to vaccination, assisting in the generation
and maintenance of effector cells,28 and so may be of benefit
during influenza infection. However, the amount of fluid in
the lung during influenza and in other lung infections may
inhibit its passage into the body.
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